89bio, Inc. (ETNB)

89bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	32.61	28.97	21.45	19.41	13.16	5.29
Research & Development	147.35	122.23	80.8	70.33	36.2	21.35
Operating Expenses	179.96	151.2	102.25	89.74	49.36	26.64
Operating Income	-179.96	-151.2	-102.25	-89.74	-49.36	-26.64
Interest Expense / Income	3.58	4.79	1.92	0.67	0	0
Other Expense / Income	-22.47	-17.68	-2.16	-0.15	0.2	30.56
Pretax Income	-161.07	-138.32	-102.01	-90.27	-49.56	-57.2
Income Tax	3.96	3.87	0.02	-0.15	-0.06	0.22
Net Income	-165.03	-142.19	-102.03	-90.12	-49.5	-57.42
Shares Outstanding (Basic)	96	71	35	20	16	2
Shares Outstanding (Diluted)	96	71	35	20	16	2
Shares Change	80.26%	104.48%	73.18%	24.93%	586.28%	428.25%
EPS (Basic)	-2.01	-2.00	-2.93	-4.48	-3.08	-24.49
EPS (Diluted)	-2.01	-2.00	-2.93	-4.48	-3.08	-24.49
Free Cash Flow	-138.83	-129.19	-81.1	-76.84	-46.37	-25.6
Free Cash Flow Per Share	-1.45	-1.81	-2.33	-3.82	-2.88	-10.92
EBITDA	-157.09	-133.26	-99.85	-89.52	-49.5	-57.19
Depreciation & Amortization	0.4	0.27	0.24	0.08	0.06	0.02
EBIT	-157.49	-133.53	-100.09	-89.6	-49.56	-57.2

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).